Litcius/Paper detail

HSP60 in cancer: a promising biomarker for diagnosis and a potentially useful target for treatment

Bo Sun, Ganghui Li, Qing Yu, Dongchun Liu, Xing Tang

2021Journal of drug targeting38 citationsDOI

Abstract

Heat shock proteins (HSPs), most of which are molecular chaperones, are highly conserved proteins produced by cells under physiological stress or pathological conditions. HSP60 (57-69 kDa) can promote or inhibit cell apoptosis through different mechanisms, and its abnormal expression is also related to tumour cell metastasis and drug resistance. In recent years, HSP60 has received increasing attention in the field of cancer research due to its potential as a diagnostic and prognostic biomarker or therapeutic target. However, in different types of cancer, the specific mechanisms of abnormally expressed HSP60 in tumour carcinogenesis and drug resistance are complicated and still require further study. In this article, we comprehensively review the regulative mechanisms of HSP60 on apoptosis, its applications as a cancer diagnostic biomarker and a therapeutic target, evidence of involvement in tumour resistance and the applications of exosomal HSP60 in liquid biopsy. By evaluating the current findings of HSP60 in cancer research, we highlight some core issues that need to be addressed for the use of HSP60 as a diagnostic or prognostic biomarker and therapeutic target in certain types of cancer.

Topics & Concepts

HSP60BiomarkerHeat shock proteinCancerMedicineCancer researchCarcinogenesisDrug resistanceCellMetastasisCancer biomarkersTumour heterogeneityBioinformaticsCancer cellImmunologyHsp27BiologyCell typeBiomarker discoveryPathologicalApoptosisComputational biologyHeat shock proteins researchEndoplasmic Reticulum Stress and DiseaseAmoebic Infections and Treatments
HSP60 in cancer: a promising biomarker for diagnosis and a potentially useful target for treatment | Litcius